ISSN: 1859 - 2872
The study on changes of serum IL-17A and hs-CRP concentration of psoriasis vulgaris patients treated by secukinumab
Main Article Content
Keywords
Abstract
Objective: To evaluate changes of serum IL-17A and hs-CRP levels in secukinumab-treated patients with moderate to severe psoriasis vulgaris. Subject and method: A clinical study with 50 moderate to severe psoriasis vulgaris patients treated with secukinumab 300mg. Serum IL-17A and hs-CRP levels were measured with ELISA method with a kit supported by Abcam, USA was performed at 0, 12th and 24th week. Result: The concentration of Il-17 decreases statiscally significant, after 12 weeks from 29.89 to 23.82 (p<0.01), after 24 weeks was 6.05 (p<0.001), and hs-CRP also decreased with time with statistical significance, after 12 weeks from 8.14 to 4.27 (p<0.001) and after 24 weeks was 2.13 (p<0.001). Conclusion: Secukinumab not only rapidly eliminated psoriatic lesions but also displayed its competences in decreasing serum IL-17A and hs-CRP levels after treatment, which subsequently mitigates risks of cardiovascular diseases and deaths on psoriatic patients.
Article Details
References
2. Trương Lê Anh Tuấn, Lê Ngọc Diệp (2012) Mối liên quan giữa bệnh vảy nến và hội chứng chuyển hóa. Y học TP. Hồ Chí Minh; tập 16, phụ bản số 1, tr. 268-274.
3. Benjamin L, Yevgeniy B et al (2018) Interleukin-17, inflammation, and cardiovascular risk in patients with psoriasis. In J Am Acad D Ermatol 79(2): 345-352.
4. Ryan C, Kirby B (2015) Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 33: 41-55.
5. Boehncke WH, Boehncke S, Tobin AM, Kirby B (2011) The 'psoriatic march': A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20: 303-307.
6. Myers GL, Rifai N et al (2004) CDC/AHA Workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Report from the laboratory science discussion group. In Circulation 110(25): 545-549.
7. Van de Kerkhof PCM, Nestlé FO (2018) Psoriasis. In Dermatology, 4th edition, Elsevier Saunders: 138-160.
8. Charles W, Lynde, Ronald Vender et al (2014) Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. In J Am Acad Dermatol: 1-10.
9. Akimichi M, Yumiko T et al (2020 Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab. In Journal of Dermatology 47: 452-457
10. Gottlieb B, Sigurgeirsson et al (2014) Secukinumab Reduces Hs-CRP levels in subjects with moderate-To-severe plaque psoriasis and concomitant psoriatic arthritis: A sub-analysis from the Phase 3 erasure study. In Annals of the Rheumatic Diseases 73: 1047-1048.
11. Gerdes S, Pinter A, Papavassilis C, Reinhardt M (2020) Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. In J Eur Acad Dermatol Venereol 34(3): 533-541.
Article Sidebar
